7-(3-hydroxyphenyl)-2-naphthol

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 7-(3-hydroxyphenyl)-2-naphthol
• 英文别名: 7-(3-hydroxyphenyl)naphthalen-2-ol
• 化学式: C₁₆H₁₂O₂
• 分子量: 236.27
• InChiKey: VEQWNMMVQWDERW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  ——	2-methoxy-7-(3-methoxyphenyl)naphthalene	550998-01-1	C18H16O2	264.324

反应信息

• 作为产物：
  描述：

  2-methoxy-7-(3-methoxyphenyl)naphthalene 在 C₆H₅N*HCl 作用下， 反应 2.0h， 以28%的产率得到7-(3-hydroxyphenyl)-2-naphthol
  参考文献：
  名称：

  ERβ Ligands. 3. Exploiting Two Binding Orientations of the 2-Phenylnaphthalene Scaffold To Achieve ERβ Selectivity

  摘要：

  The 2-phenylnaphthalene scaffold was explored as a simplified version of genistein in order to identify ER selective ligands. With the aid of docking studies, positions 1, 4, and 8 of the 2-phenylnaphthalene template were predicted to be the most potentially influential positions to enhance ER selectivity using two different binding orientations. Both orientations have the phenol moiety mimicking the A-ring of genistein. Several compounds predicted to adopt orientations similar to that of genistein when bound to ERbeta were observed to have slightly higher ER affinity and selectivity than genistein. The second orientation we exploited, which was different from that of genistein when bound to ERbeta, resulted in the discovery of several compounds that had superior ER selectivity and affinity versus genistein. X-ray structures of two ER selective compounds (i.e., 15 and 47) confirmed the alternate binding mode and suggested that substituents at positions 1 and 8 were responsible for inducing selectivity. One compound (i.e., 47, WAY-202196) was further examined and found to be effective in two models of inflammation, suggesting that targeting ER may be therapeutically useful in treating certain chronic inflammatory diseases.

  DOI：

  10.1021/jm058173s

文献信息

• Substituted phenyl naphthalenes as estrogenic agents
  申请人：Wyeth

  公开号：US20030181519A1

  公开（公告）日：2003-09-25

  This invention provides estrogen receptor modulators of formula I, having the structure 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 , are as defined in the specification, or a pharmaceutically acceptable salt thereof.

  这项发明提供了具有结构的式I的雌激素受体调节剂 1 其中 R 1 ，R 2 ，R 3 ，R 4 ，R 5 ，R 6 ，R 7 ，R 8 ，R 9 和R 10 如规范中所定义，或其药用可接受盐。
• Design, Synthesis, and Biological Evaluation of (Hydroxyphenyl)naphthalene and -quinoline Derivatives: Potent and Selective Nonsteroidal Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1) for the Treatment of Estrogen-Dependent Diseases
  作者：Martin Frotscher、Erika Ziegler、Sandrine Marchais-Oberwinkler、Patricia Kruchten、Alexander Neugebauer、Ludivine Fetzer、Christiane Scherer、Ursula Müller-Vieira、Josef Messinger、Hubert Thole、Rolf W. Hartmann

  DOI：10.1021/jm701447v

  日期：2008.4.1

  Human 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) catalyzes the reduction of the weak estrogen estrone (E1) to the highly potent estradiol (E2). This reaction takes place in the target cell where the estrogenic effect is exerted via the estrogen receptor (ER). Estrogens, especially E2, are known to stimulate the proliferation of hormone-dependent diseases. 17beta-HSD1 is overexpressed

  人类17β-羟基类固醇脱氢酶1（17beta-HSD1）催化将弱雌激素雌酮（E1）还原为强效雌二醇（E2）。该反应在靶细胞中发生，在靶细胞中通过雌激素受体（ER）发挥雌激素作用。已知雌激素，尤其是E2会刺激激素依赖性疾病的扩散。17beta-HSD1在许多乳腺肿瘤中过表达。因此，它是治疗这些疾病的有吸引力的靶标。基于配体和结构的药物设计导致发现17beta-HSD1的新型，选择性和有效抑制剂。合成了苯基取代的双环部分，作为类固醇底物的模拟物。使用计算方法来了解它们与蛋白质的相互作用。
• PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION
  申请人：CHANG Chien-Neng

  公开号：US20090010884A1

  公开（公告）日：2009-01-08

  The present invention provides compositions and methods for preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion using one or more estrogenic agents.

  本发明提供了使用一个或多个雌激素类药物预防、治疗或抑制皮肤炎症性疾病、紊乱或状况以及与胶原蛋白流失相关的疾病、紊乱或状况的组合物和方法。
• 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases
  申请人：Hartmann Rolf

  公开号：US20100204234A1

  公开（公告）日：2010-08-12

  The invention relates to the use of non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment and prophylaxis of hormone-dependent, particularly estrogen-dependent, diseases. The invention further relates to suitable inhibitors and to a method for the production thereof.

  该发明涉及使用非甾体17β-羟基类固醇脱氢酶1抑制剂治疗和预防激素依赖性疾病，特别是雌激素依赖性疾病。该发明还涉及适当的抑制剂以及生产方法。
• Novel uses for estrogen beta agonists
  申请人：Day Mark

  公开号：US20060135574A1

  公开（公告）日：2006-06-22

  This invention provides methods for treating cognitive diseases or disorders and symptoms thereof with estrogen beta selective agonists.

  本发明提供了利用雌激素 beta 选择性激动剂治疗认知疾病或紊乱及其症状的方法。